GlassScriptPhysician profile
Igor N Bedarev
NPI 1497069918
$532.68
in general payments reported to CMS, 2019-2025
12 companies · $315 in 2025
The $315 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $218 · 2025: $315.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $533.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $532.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $115.98 | 2024-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $106.21 | 2024-2025 | |
| Lilly USA, LLC | $60.94 | 2024-2025 | Mounjaro, Jardiance |
| Amgen INC. | $59.64 | 2024-2025 | Otezla, Repatha, Otezla |
| Dexcom, INC. | $39.25 | 2024-2025 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $37.22 | 2024-2025 | Veozah |
| Novo Nordisk INC | $26.81 | 2024-2025 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.23 | 2025 | Jardiance |
| Sumitomo Pharma America, INC. | $18.00 | 2025 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $17.82 | 2024 | |
| Exact Sciences Corporation | $15.59 | 2025 | The Cologuard Plus Collection Kit |
| Novartis Pharmaceuticals Corporation | $14.99 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Igor Bedarev listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.